Skip to main content
. 2021 Dec 15;131(24):e145501. doi: 10.1172/JCI145501

Figure 3. The selective JAK1/2 inhibitor baricitinib permits alloengraftment in CD45-SAP–conditioned mice.

Figure 3

(A) Schematic for baricitinib and CD45-SAP treatment in allo-HSCT models. (B) Peripheral blood donor chimerism for individual mice in the miHA-mismatched and MHC-mismatched models, pooled from 2 experiments. (C) Overall donor chimerism in MHC-mismatched HSCT combining CD45-SAP with PTCy or PBS, pooled from 2 experiments. (D) Schematic and results for MHC-mismatched HSCT combining CD45-SAP, daily baricitinib, and pretransplant TCD, pooled from 3 experiments. (E) Schematic and results for MHC-mismatched HSCT combining CD45-SAP with continuously infused JAK1/2 inhibitors, pooled from 3 experiments. X indicates mouse death or euthanasia. Insets display the proportion of successfully engrafted mice at t = 6 months. Repeated measures ANOVA (B and C) and a mixed effects model (D and E) were used for statistical comparisons of overall donor chimerism. *P < 0.05; ***P < 0.001.